Meta-regression:
Due to the high heterogeneity found in the analyses, a meta-regression
analysis was conducted. A meta-regression revealed a statistically
significant association between early gestational age at initiation of
pravastatin treatment and decreased risk for the development of
preeclampsia (R2=1) and NICU admission
(R2=0.33). Statistically significant associations were
not found between higher pravastatin dose to prolongation of pregnancy
from study entry to delivery, birth weight, perinatal death or NICU
admission. Statistically significant associations were not found between
earlier gestational age at initiation of pravastatin treatment to
prolongation of pregnancy from study entry to delivery, birth weight or
perinatal death (Figure S4-S13).